DaVita HealthCare Partners (DVA) stock plummeted 9.58% in after-hours trading on Thursday, despite reporting better-than-expected fourth-quarter earnings. The kidney dialysis provider's decline suggests investors were disappointed with the company's full-year 2025 earnings guidance.
For the fourth quarter, DaVita reported adjusted earnings per share of $2.24, surpassing analysts' estimates of $2.14. However, the company's guidance for full-year 2025 earnings in the range of $10.20 to $11.30 per share may have fallen short of investors' expectations, triggering the sharp sell-off in after-hours trading.
While DaVita's Q4 revenue of $3.29 billion and other financial metrics were solid, the market reaction indicates that investors were seeking stronger earnings projections from the healthcare company for the coming year. The after-hours plunge underscores the importance of forward guidance and meeting market expectations, even when a company reports better-than-expected quarterly results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.